Acutis Diagnostics has selected the SOPHiA DDM technology from Sophia Genetics for the development of a new next-generation sequencing (NGS) test.

The new genomic assay will be created by pairing SOPHiA DDM for Hereditary Cancers Solution with Acutis’ laboratory analysis technologies.

The new test is expected to help with genomic screening for the recruitment of patients to oncology clinical studies, as well as for retrospective analyses to support the explanation of clinical outcomes and drug target discovery.    

Acutis Diagnostics chief scientific officer and executive vice-president Dr Abdel Halim said: “The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled.

“Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.” 

The NGS-based Sophia Genetics hereditary cancer solutions apply artificial intelligence and machine learning combined with patented technologies to analyse raw NGS data and offer simplified insights.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clinical researchers can also use the technology to precisely characterise the complex mutational landscape linked with key hereditary cancer disorders.  

Sophia Genetics chief revenue officer Ken Freedman said: “The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole.” 

Earlier this month, Sophia Genetics also joined forces with Agilent Technologies on a comprehensive solution for cancer analysis.